Celltrion’s Yuflyma receives US FDA approval for multiple conditions
Pharmaceutical Technology
MAY 25, 2023
Yuflyma represents the company’s fifth biosimilar and second anti-TNF biosimilar to receive US FDA approval. The regulatory approval was based on a comprehensive data package of preclinical, analytical and clinical trials. It will be offered to patients in prefilled syringe and autoinjector administration options.
Let's personalize your content